Hikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,458.40 and traded as high as GBX 1,667. Hikma Pharmaceuticals shares last traded at GBX 1,659.74, with a volume of 44,098,535 shares.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HIK. Jefferies Financial Group raised their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Berenberg Bank raised their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Citigroup lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of GBX 2,060.

Hikma Pharmaceuticals Trading Up 0.7%

The business has a fifty day simple moving average of GBX 1,571.46 and a 200 day simple moving average of GBX 1,460.31. The stock has a market cap of £3.42 billion, a price-to-earnings ratio of 9.04, a PEG ratio of 2.38 and a beta of 0.66. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98.

Insider Activity

In related news, insider Tobias Hestler acquired 7,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of GBX 1,648 per share, with a total value of £123,600. 22.04% of the stock is owned by corporate insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.